

Refine Search

Search Results -

Terms	Documents
L23 same L22	29

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L24

Search History

DATE: Tuesday, November 14, 2006 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L24</u>	L23 same L22	29	<u>L24</u>
<u>L23</u>	("polyethylene oxide" or "polyox" or explotab or disintegrant or crosopvidone or "croscarmellose sodium" or "Ac-Di-Sol")	76138	<u>L23</u>
<u>L22</u>	(mixture or blend\$4 or combin\$7) near10 (opioid or opiate or alfentanil or buprenorphine or butorphanol or carfentanil or codeine or dezocine or diacetylmorphine or dihydrocodeine or dihydromorphine or diprenorphine or etorphine or fentanyl or hydrocodone or hydromorphone or "beta hydroxy 3-methylfentanyl" or "levo-alpha-acetylmethadol" or levorphanol or lofentanil or meperidine or methadone or morphine or nalbuphine or oxycodone or oxymorphone or pentazocine or pethidine or propoxyphene or remifentanil or sufentanil or tilidine or tramadol)	3636	<u>L22</u>
<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>			
<u>L21</u>	L20 and ("polyethylene oxide" or "polyox" or explotab or disintegrant or crosopvidone or "croscarmellose sodium" or "Ac-Di-Sol")	15	<u>L21</u>

	L19 and (opioid or opiate or alfentanil or buprenorphine or butorphanol or carfentanil or codeine or dezocine or diacetylmorphine or dihydrocodeine or dihydromorphine or diprenorphine or etorphine or fentanyl or hydrocodone or hydromorphone or "beta hydroxy 3-methylfentanyl" or "levo-alpha-acetylmethadol" or levorphanol or lofentanil or meperidine or methadone or morphine or nalbuphine or oxycodone or oxymorphone or pentazocine or pethidine or propoxyphene or remifentanil or sufentanil or tilidine or tramadol).	86	<u>L20</u>
<u>L19</u>	424/456.ccls.	866	<u>L19</u>
	L17 and (("polyethylene oxide" or "polyox" or explotab or disintegrant or crospovidone or "croscarmellose sodium" or "Ac-Di-Sol") same (opioid or opiate or alfentanil or buprenorphine or butorphanol or carfentanil or codeine or dezocine or diacetylmorphine or dihydrocodeine or dihydromorphine or diprenorphine or etorphine or fentanyl or hydrocodone or hydromorphone or "beta hydroxy 3-methylfentanyl" or "levo-alpha-acetylmethadol" or levorphanol or lofentanil or meperidine or methadone or morphine or nalbuphine or oxycodone or oxymorphone or pentazocine or pethidine or propoxyphene or remifentanil or sufentanil or tilidine or tramadol))	12	<u>L18</u>
<u>L18</u>	L16 and ("polyethylene oxide" or "polyox" or explotab or disintegrant or crospovidone or "croscarmellose sodium" or "Ac-Di-Sol")	209	<u>L17</u>
<u>L17</u>	L14 and (opioid or opiate or alfentanil or buprenorphine or butorphanol or carfentanil or codeine or dezocine or diacetylmorphine or dihydrocodeine or dihydromorphine or diprenorphine or etorphine or fentanyl or hydrocodone or hydromorphone or "beta hydroxy 3-methylfentanyl" or "levo-alpha-acetylmethadol" or levorphanol or lofentanil or meperidine or methadone or morphine or nalbuphine or oxycodone or oxymorphone or pentazocine or pethidine or propoxyphene or remifentanil or sufentanil or tilidine or tramadol)	388	<u>L16</u>
<u>L16</u>	L14 and (opioid or opiate)	137	<u>L15</u>
<u>L15</u>	424/464.ccls.	2760	<u>L14</u>
<u>L14</u>	L12 and ("polyethylene oxide" or "polyox" or explotab or disintegrant or crospovidone or "croscarmellose sodium" or "Ac-Di-Sol")	69	<u>L13</u>
<u>L13</u>	L10 and (opioid or opiate or alfentanil or buprenorphine or butorphanol or carfentanil or codeine or dezocine or diacetylmorphine or dihydrocodeine or dihydromorphine or diprenorphine or etorphine or fentanyl or hydrocodone or hydromorphone or "beta hydroxy 3-methylfentanyl" or "levo-alpha-acetylmethadol" or levorphanol or lofentanil or meperidine or methadone or morphine or nalbuphine or oxycodone or oxymorphone or pentazocine or pethidine or propoxyphene or remifentanil or sufentanil or tilidine or tramadol)	215	<u>L12</u>
<u>L12</u>	L10 and (opioid or opiate)	90	<u>L11</u>
<u>L11</u>	424/451.ccls.	1852	<u>L10</u>
<u>L10</u>	L8 and (opioid or opiate)	5	<u>L9</u>
<u>L9</u>	424/408.ccls.	581	<u>L8</u>
<u>L8</u>	L5 and (opioid or opiate or analges\$3)	34	<u>L7</u>
<u>L7</u>	L5 and (opi\$4 or "polyethelene oxide" or disintegrant or crospovidone or "sodium starch glycolate" or Explotab or "croscarmellose sodium" or "Ac-Di-Sol" or ((nasal or mucos\$3) near5 irritant))	50	<u>L6</u>
<u>L6</u>	424/408.ccls.	581	<u>L5</u>
<u>L5</u>	(Dilip near Wadgaonkar) AND @pd>20060511	0	<u>L4</u>
<u>L4</u>			

L3 (Divya near Tewari) AND @pd>20060511
L2 (David near Dixon) AND @pd>20060511
L1 (Vijai near Kumar) AND @pd>20060511

0 L3
5 L2
1 L1

END OF SEARCH HISTORY



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Tuesday
Date: 11/14/2006

Time: 19:16:44

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

Dixon

First Name

David

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 19:16:17 ON 14 NOV 2006)

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 19:18:47 ON 14 NOV 2006

L1 137 S (OPIOID OR OPIATE) (P) (CROSPVIDONE OR (POLYETHYLENE(W)OXIDE
L2 80 S L1 AND (MORPHINE OR OXYCODONE OR HYDROMORPHINE OR HYDROCODEIN
L3 9 S L2 AND ((MORPHINE OR OXYCODONE OR HYDROMORPHONE OR HYDROCODEI
L4 9 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)

=> d que 11

L1 137 SEA (OPIOID OR OPIATE) (P) (CROSPVIDONE OR (POLYETHYLENE(W)
OXIDE) OR PEG OR DISINTEGRANT OR (CROSCARMELLOSE(W) SODIUM) OR
(NASAL (5A) IRRITANT))

=> d que 12

L1 137 SEA (OPIOID OR OPIATE) (P) (CROSPVIDONE OR (POLYETHYLENE(W)
OXIDE) OR PEG OR DISINTEGRANT OR (CROSCARMELLOSE(W) SODIUM) OR
(NASAL (5A) IRRITANT))
L2 80 SEA L1 AND (MORPHINE OR OXYCODONE OR HYDROMORPHINE OR HYDROCODE
INE)

=> d que 13

L1 137 SEA (OPIOID OR OPIATE) (P) (CROSPVIDONE OR (POLYETHYLENE(W)
OXIDE) OR PEG OR DISINTEGRANT OR (CROSCARMELLOSE(W) SODIUM) OR
(NASAL (5A) IRRITANT))
L2 80 SEA L1 AND (MORPHINE OR OXYCODONE OR HYDROMORPHINE OR HYDROCODE
INE)
L3 9 SEA L2 AND ((MORPHINE OR OXYCODONE OR HYDROMORPHONE OR
HYDROCODEINE) (P) (DISINTEGRANT OR EXPLOTAB OR CROSPVIDONE OR
POLYOX OR (CROSCARMELLOSE(W) SODIUM) OR SURFACTANT OR SDS OR
(SODIUM(W) DODECYL(W) SULFATE)))

L4 ANSWER 1 OF 9 USPATFULL on STN

TI Controlled release formulations of opioid and nonopioid analgesics
AB Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

ACCESSION NUMBER: 2006:294556 USPATFULL

TITLE: Controlled release formulations of opioid and nonopioid analgesics

INVENTOR(S): Cruz, Evangeline, Hayward, CA, UNITED STATES
Ayer, Atul D., Palo Alto, CA, UNITED STATES
Pollock, Brenda J., Cupertino, CA, UNITED STATES
Garcia, Carmelita, Newark, CA, UNITED STATES
Li, Sherry, Cupertino, CA, UNITED STATES
Wong, Alfredo M., Sunnyvale, CA, UNITED STATES
Hamel, Lawrence G., Mountain View, CA, UNITED STATES
Klein, Cheri Enders, Northbrook, IL, UNITED STATES
Qiu, Yihong, Vernon Hills, IL, UNITED STATES
Huang, Ye, Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006251721	A1	20061109
APPLICATION INFO.:	US 2006-480124	A1	20060630 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-949141, filed on 24 Sep 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-571238P	20040514 (60)
	US 2003-506195P	20030926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Page(s)	
LINE COUNT:	5203	

L4 ANSWER 2 OF 9 USPATFULL on STN

TI Methods and compositions for deterring abuse of orally administered pharmaceutical products
AB This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended to deter abuse of the active drug substance via injection, nasal inhalation or consumption of quantities of the dosage unit exceeding the usual therapeutically effective dose.

ACCESSION NUMBER: 2006:208386 USPATFULL

TITLE: Methods and compositions for deterring abuse of orally administered pharmaceutical products
INVENTOR(S): Emigh, James F., Palantine, IL, UNITED STATES
Reddick, Andrew D., Exton, PA, UNITED STATES
Spivey, Ron J., Cooper City, FL, UNITED STATES
PATENT ASSIGNEE(S): Acura Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006177380	A1	20060810
APPLICATION INFO.:	US 2005-136636	A1	20050524 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-663973P	20050322 (60)
	US 2005-643637P	20050113 (60)
	US 2004-639831P	20041228 (60)
	US 2004-630991P	20041124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,
PHILADELPHIA, PA, 19103-2921, US
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 9 USPATFULL on STN

TI Methods and compositions for deterring abuse of orally administered pharmaceutical products

AB This invention relates to an abuse deterrent formulation of an oral dosage form of a therapeutically effective amount of any active drug substance that can be subject to abuse combined with a gel forming polymer, a nasal mucosal irritating surfactant and a flushing agent. Such a dosage form is intended to deter abuse of the active drug substance via injection, nasal inhalation or consumption of quantities of the dosage unit exceeding the usual therapeutically effective dose.

ACCESSION NUMBER: 2006:130690 USPATFULL

TITLE: Methods and compositions for deterring abuse of orally administered pharmaceutical products

INVENTOR(S): Emigh, James F., Palantine, IL, UNITED STATES
Leech, Ronald L. JR., Plymouth, IN, UNITED STATES
Reddick, Andrew D., Exton, PA, UNITED STATES
Spivey, Ron J., Cooper City, FL, UNITED STATES

PATENT ASSIGNEE(S): Acura Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006110327	A1	20060525
APPLICATION INFO.:	US 2005-287012	A1	20051123 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2005-136636, filed on 24 May 2005, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-693898P	20050624 (60)
	US 2005-663973P	20050322 (60)
	US 2005-643637P	20050113 (60)
	US 2004-639831P	20041228 (60)
	US 2004-630991P	20041124 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921, US

NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2687
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 9 USPATFULL on STN

TI Method and compositions for the treatment of gastrointestinal disorders
AB Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

ACCESSION NUMBER: 2006:111711 USPATFULL

TITLE: Method and compositions for the treatment of gastrointestinal disorders

INVENTOR(S): Currie, Mark G., Sterling, MA, UNITED STATES
Mahajan-Miklos, Shalina, Palo Alto, CA, UNITED STATES
Sun, Li Jing, New York, NY, UNITED STATES
Kurtz, Caroline, Sudbury, MA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2006094658	A1	20060504
APPLICATION INFO.:	US 2005-54072	A1	20050208 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-868744, filed on 14 Jun 2004, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2003-478492P	20030613 (60)
	US 2003-532361P	20031223 (60)
	US 2004-571386P	20040514 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 221 Drawing Page(s)
LINE COUNT: 3301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 9 USPATFULL on STN

TI Methods for the treatment of back pain
AB Methods and materials, including novel compositions, dosage forms and methods of administration, useful for treating back pain using opioid antagonists, including combinations of opioid antagonists and opioid agonists. Methods and materials comprising opioid antagonists or combinations opioid antagonists and agonists may optionally include one or more additional therapeutic agents.

ACCESSION NUMBER: 2006:10625 USPATFULL

TITLE: Methods for the treatment of back pain

INVENTOR(S): Friedmann, Nadav, Lafayette, CA, UNITED STATES
Barbier, Remi, San Francisco, CA, UNITED STATES

Schoenhard, Grant L., San Carlos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006009478	A1	20060112
APPLICATION INFO.:	US 2005-89283	A1	20050323 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-966703, filed on 15 Oct 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-511841P	20031015 (60)
	US 2004-566189P	20040427 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCANDREWS HELD & MALLOY, LTD, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661, US	
NUMBER OF CLAIMS:	110	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	10857	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 6 OF 9 USPATFULL on STN

TI Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain

AB Methods and materials, including novel compositions, dosage forms and methods of administration, useful for treating arthritic conditions, inflammation associated with a chronic condition, and/or chronic pain, including pain from arthritis and inflammation, using opioid antagonists, including combinations of opioid antagonists and opioid agonists. Methods and materials comprising opioid antagonists or combinations opioid antagonists and agonists may optionally include one or more additional therapeutic agents.

ACCESSION NUMBER: 2005:281602 USPATFULL

TITLE: Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain

INVENTOR(S): Schoenhard, Grant L., San Carlos, CA, UNITED STATES
Friedmann, Nadav, Lafayette, CA, UNITED STATES

PATENT ASSIGNEE(S): Pain Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005245557	A1	20051103
APPLICATION INFO.:	US 2004-966703	A1	20041015 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-511841P	20031015 (60)
	US 2004-566189P	20040427 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCANDREWS HELD & MALLOY, LTD, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661, US	
NUMBER OF CLAIMS:	65	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	6326	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 7 OF 9 USPATFULL on STN

TI Controlled release formulations of opioid and nonopioid analgesics

AB Sustained release dosage forms for twice daily oral dosing to a human

patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

ACCESSION NUMBER: 2005:182999 USPATFULL
 TITLE: Controlled release formulations of opioid and nonopioid analgesics
 INVENTOR(S): Cruz, Evangeline, Hayward, CA, UNITED STATES
 Ayer, Atul D., Palo Alto, CA, UNITED STATES
 Pollock, Brenda J., Cupertino, CA, UNITED STATES
 Garcia, Carmelita, Newark, CA, UNITED STATES
 Li, Sherry, Cupertino, CA, UNITED STATES
 Wong, Alfredo M., Sunnyvale, CA, UNITED STATES
 Hamel, Lawrence G., Mountain View, CA, UNITED STATES
 Klein, Cheri Enders, Northbrook, IL, UNITED STATES
 Qiu, Yihong, Vernon Hills, IL, UNITED STATES
 Huang, Ye, Gurnee, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158382	A1	20050721
APPLICATION INFO.:	US 2004-949141	A1	20040924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-571238P	20040514 (60)
	US 2003-506195P	20030926 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US	
NUMBER OF CLAIMS:	121	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Page(s)	
LINE COUNT:	5664	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 9 USPATFULL on STN
 TI Methods and compositions for deterring abuse of opioid containing dosage forms
 AB This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
 ACCESSION NUMBER: 2005:130609 USPATFULL
 TITLE: Methods and compositions for deterring abuse of opioid containing dosage forms
 INVENTOR(S): Kumar, Vijai, Morris Plains, NJ, UNITED STATES
 Dixon, David, Woodside, NY, UNITED STATES
 Tewari, Divya, Suffern, NY, UNITED STATES
 Wadgaonkar, Dilip B., Suffern, NY, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005112067 A1 20050526
 APPLICATION INFO.: US 2003-723654 A1 20031126 (10)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,
 PHILADELPHIA, PA, 19103-2921, US
 NUMBER OF CLAIMS: 43
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 9 Drawing Page(s)
 LINE COUNT: 1371
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 9 USPATFULL on STN

TI Opioid antagonist compositions and dosage forms

AB The present invention is directed to novel dosage forms, pharmaceutical
 compositions, kits, and methods of administration of an opioid
 antagonist in an amount of at least about 0.0001 mg to about or less
 than about 1.0 mg, including from about 0.0001 mg to less than about 0.5
 mg. Solid oral dosage forms are disclosed consisting essentially of an
 opioid antagonist or alternatively comprising an opioid antagonist and
 another active ingredient, such as an opioid agonist. Immediate release
 oral dosage forms are disclosed that release all or a substantial
 percentage of opioid antagonist, and another active ingredient when
 present, in a desired time. Concurrent release dosage forms are
 disclosed that provide concurrent release of an opioid antagonist and
 another active ingredient.

ACCESSION NUMBER: 2003:271539 USPATFULL

TITLE: Opioid antagonist compositions and dosage forms

INVENTOR(S): Sherman, Barry, Hillsborough, CA, UNITED STATES
 Remien, Mary, San Francisco, CA, UNITED STATES
 Barbier, Remi, San Francisco, CA, UNITED STATES
 McGinity, James W., Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191147	A1	20031009
APPLICATION INFO.:	US 2002-119615	A1	20020409 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MCANDREWS HELD & MALLOY, LTD, 500 WEST MADISON STREET, SUITE 3400, CHICAGO, IL, 60661		
NUMBER OF CLAIMS:	171		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	3686		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			